Minerva Neurosciences Inc (NASDAQ:NERV) – Stock analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for shares of Minerva Neurosciences in a research report issued on Monday. Jefferies Group analyst B. Amin forecasts that the biopharmaceutical company will earn ($0.30) per share for the quarter. Jefferies Group also issued estimates for Minerva Neurosciences’ Q2 2018 earnings at ($0.35) EPS, Q3 2018 earnings at ($0.39) EPS, Q4 2018 earnings at ($0.41) EPS and FY2022 earnings at ($0.08) EPS.
A number of other equities research analysts also recently weighed in on NERV. BidaskClub raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine downgraded Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $12.92.
In related news, CFO Geoff Race sold 5,829 shares of Minerva Neurosciences stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $5.79, for a total transaction of $33,749.91. Following the sale, the chief financial officer now directly owns 197,698 shares of the company’s stock, valued at $1,144,671.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last three months, insiders have sold 12,590 shares of company stock worth $73,073. 21.60% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in NERV. Teachers Advisors LLC grew its position in Minerva Neurosciences by 46.3% during the second quarter. Teachers Advisors LLC now owns 45,691 shares of the biopharmaceutical company’s stock worth $404,000 after buying an additional 14,465 shares in the last quarter. TIAA CREF Investment Management LLC grew its position in Minerva Neurosciences by 69.6% during the second quarter. TIAA CREF Investment Management LLC now owns 84,245 shares of the biopharmaceutical company’s stock worth $746,000 after buying an additional 34,572 shares in the last quarter. Nationwide Fund Advisors grew its position in Minerva Neurosciences by 14.2% during the second quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,616 shares in the last quarter. New York State Common Retirement Fund grew its position in Minerva Neurosciences by 62.4% during the second quarter. New York State Common Retirement Fund now owns 28,100 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 10,799 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in Minerva Neurosciences by 27.9% during the second quarter. Northern Trust Corp now owns 298,507 shares of the biopharmaceutical company’s stock worth $2,641,000 after purchasing an additional 65,056 shares during the period. 70.20% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Jefferies Group Comments on Minerva Neurosciences Inc’s Q1 2018 Earnings (NERV)” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/jefferies-group-comments-on-minerva-neurosciences-incs-q1-2018-earnings-nerv.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.